Fortifeye launches Eye Pressure and Neuro Cognitive Support supplement
February 29th 2024The supplement is specifically crafted to promote healthy intraocular pressure (IOP), nurturing the well-being of retinal ganglion cells, and sustain the health of the retinal nerve fiber layer while boosting memory and concentration.
AGS 2024: Leon Herndon, MD, President of AGS, previews the annual meeting
February 29th 2024Leon Herndon, MD, President of the American Glaucoma Society, sat down with David Hutton of Ophthalmology Times to discuss the AGS meeting held in Huntington Beach and what attendees can expect as well as new and exciting information to come from the meeting.
PulseSight Therapeutics launches to advance non-viral gene therapies for severe retinal diseases
February 28th 2024According to the company, its proprietary non-viral gene therapy platform with minimally invasive delivery technology is providing long lasting gene expression and favorable distribution in the retina.
Study: Treatment developed to dramatically slow progression of blindness-causing retinal diseases
February 24th 2024Researchers have found that the interactive release of anti-inflammatory drugs depend on the level of retinal degeneration. A customized treatment approach is expected to be developed to reduce patients’ inconvenience of having multiple shots.